BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Slims down for Maintainable Weight reduction - 2NASA's Perseverance Mars rover could break the record for miles driven on another planet
- 3Must-See Attractions in Washington, D.C.
- 4Research institutions tout the value of scholarship that crosses disciplines – but academia pushes interdisciplinary researchers out
- 5Emergency services search for five people last seen in missing Jeep
- One month of war on Iran cost Arab countries up to $194bn: UNDP
- Unsold Rams May Be Less expensive Than You Suspect
- Smuggler who called migrants 'chickens' jailed
- Defense Minister Katz finally condemns Jewish extremist violence against Palestinians
- Fundamental Home Machines: An Easy to understand Determination Guide
- 2024's Hot Games: Must-Play Titles of the Year
- Congolese rape survivors search in vain for medicine after USAID cuts
- UB professor shares his experience on almost becoming an astronaut
- Turning into a Sharp Financial backer: Individual budget Wins
